Q2 EPS Estimates for Oncobiologics Lifted by Brookline Cap M

Oncobiologics, Inc. (NASDAQ:OTLK) – Investment analysts at Brookline Cap M lifted their Q2 2026 earnings per share estimates for Oncobiologics in a research report issued on Monday, March 16th. Brookline Cap M analyst K. Dolliver now expects that the company will post earnings per share of ($0.14) for the quarter, up from their prior estimate of ($0.18). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Cap M also issued estimates for Oncobiologics’ Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.62) EPS and FY2027 earnings at ($0.17) EPS.

Oncobiologics (NASDAQ:OTLK) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The company had revenue of ($1.21) million for the quarter, compared to analyst estimates of $3.14 million.

OTLK has been the topic of a number of other research reports. HC Wainwright reiterated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a research report on Wednesday, February 18th. Ascendiant Capital Markets decreased their price target on Oncobiologics from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncobiologics in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Oncobiologics Trading Up 4.4%

OTLK stock opened at $0.35 on Thursday. The firm’s 50-day moving average is $0.45 and its two-hundred day moving average is $1.07. The company has a market capitalization of $29.17 million, a price-to-earnings ratio of -0.13 and a beta of -0.07. Oncobiologics has a 52 week low of $0.29 and a 52 week high of $3.39.

Institutional Trading of Oncobiologics

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its position in Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the last quarter. 11.20% of the stock is currently owned by institutional investors.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.